Prestige Consumer Healthcare, Inc. (PBH)
45.01
-0.25
(-0.55%)
USD |
NYSE |
Oct 05, 10:01
Prestige Consumer Healthcare Enterprise Value : 4.122B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 4.122B |
| October 01, 2026 | 4.099B |
| September 30, 2026 | 4.151B |
| September 29, 2026 | 4.192B |
| September 28, 2026 | 4.201B |
| September 25, 2026 | 4.186B |
| September 24, 2026 | 4.141B |
| September 23, 2026 | 4.154B |
| September 22, 2026 | 4.239B |
| September 21, 2026 | 4.195B |
| September 18, 2026 | 4.109B |
| September 17, 2026 | 4.180B |
| September 16, 2026 | 4.198B |
| September 15, 2026 | 4.190B |
| September 14, 2026 | 4.234B |
| September 11, 2026 | 4.202B |
| September 10, 2026 | 4.221B |
| September 09, 2026 | 4.285B |
| September 08, 2026 | 4.337B |
| September 04, 2026 | 4.454B |
| September 03, 2026 | 4.468B |
| September 02, 2026 | 4.481B |
| September 01, 2026 | 4.472B |
| August 31, 2026 | 4.431B |
| August 28, 2026 | 4.464B |
| Date | Value |
|---|---|
| August 27, 2026 | 4.404B |
| August 26, 2026 | 4.449B |
| August 25, 2026 | 4.416B |
| August 24, 2026 | 4.443B |
| August 21, 2026 | 4.409B |
| August 20, 2026 | 4.372B |
| August 19, 2026 | 4.426B |
| August 18, 2026 | 4.374B |
| August 17, 2026 | 4.349B |
| August 14, 2026 | 4.412B |
| August 13, 2026 | 4.409B |
| August 12, 2026 | 4.454B |
| August 11, 2026 | 4.517B |
| August 10, 2026 | 4.489B |
| August 07, 2026 | 4.577B |
| August 06, 2026 | 4.557B |
| August 05, 2026 | 4.488B |
| August 04, 2026 | 4.442B |
| August 03, 2026 | 4.438B |
| July 31, 2026 | 4.357B |
| July 30, 2026 | 4.345B |
| July 29, 2026 | 4.451B |
| July 28, 2026 | 4.428B |
| July 27, 2026 | 4.366B |
| July 24, 2026 | 4.331B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Supernus Pharmaceuticals, Inc. | 2.133B |
| Structure Therapeutics, Inc. | 634.14M |
| ANI Pharmaceuticals, Inc. | 1.893B |
| Corcept Therapeutics, Inc. | 12.24B |
| Veru, Inc. | 19.69M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 29.18M |
| Revenue (Quarterly) | 265.71M |
| Total Expenses (Quarterly) | 236.53M |
| EPS Diluted (Quarterly) | 0.6129 |
| Gross Profit Margin (Quarterly) | 49.11% |
| Profit Margin (Quarterly) | 10.98% |
| Earnings Yield | 7.94% |
| Operating Earnings Yield | 13.39% |
| Normalized Earnings Yield | 7.935 |